Increasing access to treatment for people living with CML and Ph+ALL

active

ACTIVE SINCE: 2016

SGDS CONTRIBUTING TO:

MEMBER COMPANIES:

Global NGOs 1

BMS collaborates with the Max Foundation to increase access to dasatinib for people living with Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) in more than 20 LMICs. This access pathway is specifically designed to help patients who are uninsured or underinsured, where product is not available commercially, where significant access hurdles exist and where local market initiatives cannot enable access to the therapy.
BMS provides dasatinib free of charge to organizations that reach a patient population with an expressed need. Organizations that are provided bulk product donations for patient must have infrastructure to be able to appropriately receive and deploy product.For example, The Max Foundation is provided with dasatinib, administered free of charge within the LMICs and in accordance with medical best practices and with the Max Access Solutions Product Donation Guidelines with an expressed need within the LMICs and in accordance with medical best practices. For example, BMS provides the Max Access Solutions Product Donation Guidelines. Max upholds high quality standards for ensuring that patient receive Product. (For more information, see The Max Access Solutions Guidelines

To date, 1,222 patients with CML and Ph+ALL have been helped in over 29 countries.

SDG 3: Good Health and Wellbeing

SDG 17: Partnerships for the Goals

Global NGOs

Geographic Reach